![Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2013/5/6/Slide03.jpg)
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
![Carfilzomib a New Option for the Treatment of Patients with Relapsed, Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent | Value-Based Cancer Care Carfilzomib a New Option for the Treatment of Patients with Relapsed, Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent | Value-Based Cancer Care](https://www.valuebasedcancer.com/images/legacy/vbcc/table_2_cafilzomib_dosing_p36.png)
Carfilzomib a New Option for the Treatment of Patients with Relapsed, Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent | Value-Based Cancer Care
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies | Haematologica
![Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2014/5/1/Slide03.jpg)
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
![Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma | Research To Practice Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2012/3/1/Slide4.jpg)
Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma | Research To Practice
![Treatment schema. *Once the Maximum Tolerated Dose was established, an... | Download Scientific Diagram Treatment schema. *Once the Maximum Tolerated Dose was established, an... | Download Scientific Diagram](https://www.researchgate.net/publication/333352515/figure/fig1/AS:817617984040960@1571946726027/Treatment-schema-Once-the-Maximum-Tolerated-Dose-was-established-an-expansion-cohort.png)
Treatment schema. *Once the Maximum Tolerated Dose was established, an... | Download Scientific Diagram
![Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors - ScienceDirect Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S245194561830429X-fx1.jpg)
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors - ScienceDirect
![A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma - Biology of Blood and Marrow Transplantation A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma - Biology of Blood and Marrow Transplantation](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/45f04c0a-553e-4db4-b3c4-8a668e8417e7/ybbmt54464-fig-0001_lrg.jpg)